Infarction adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 6,800 adverse event reports that record the MedDRA preferred term Infarction. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 170 reports in the 12 months to June 2026 and 143 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,344 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 170 (under 0.1%) record this term. Reports for male patients were 48% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 141 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Infarction name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	32
Abilify	Atypical antipsychotic	207
Abilify Maintena		154
Acetylsalicylic Acid		21
Aclasta		36
Actilyse		22
Afinitor	Kinase inhibitor	10
Aggrastat	Platelet aggregation inhibitor	53
Alteplase		20
Amlodipine	Calcium channel blocker	29
Androderm		130
Androgel		145
Apixaban	Factor Xa inhibitor	36
Aripiprazole	Atypical antipsychotic	101
Aspirin	Nonsteroidal anti-inflammatory drug	56
Atacand	Angiotensin 2 receptor blocker	15
Atacand Hct	Thiazide diuretic	14
Atenolol	beta-Adrenergic blocker	21
Atorvastatin		31
Atorvastatin calcium	HMG-CoA reductase inhibitor	18
Avandia		21
Avastin	Vascular endothelial growth factor inhibitor	23
Axiron		129
Benicar	Angiotensin 2 receptor blocker	12
Brilinta	P2Y12 platelet inhibitor	85
Brilique		10
Bupropion hydrochloride	Aminoketone	161
Carboplatin	Platinum-based drug	16
Carvedilol	alpha-Adrenergic blocker	27
Certolizumab pegol	Tumor necrosis factor blocker	16
Cialis	Phosphodiesterase 5 inhibitor	10
Clopidogrel	P2Y12 platelet inhibitor	66
Clozaril	Atypical antipsychotic	13
Co-Diovan		37
Cosentyx	Interleukin-17A antagonist	73
Crestor	HMG-CoA reductase inhibitor	41
Cyclophosphamide	Alkylating drug	14
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	11
Delatestryl		120
Depo-Testosterone	Androgen	127
Dexamethasone	Corticosteroid	31
Diovan	Angiotensin 2 receptor blocker	258
Diovan Amlo Fix		39
Diovan HCT	Angiotensin 2 receptor blocker	94
Duodopa		14
Effient	P2Y12 platelet inhibitor	36
Eliquis	Factor Xa inhibitor	90
Enbrel	Tumor necrosis factor blocker	149
Entresto	Angiotensin 2 receptor blocker	245
Exelon	Cholinesterase inhibitor	88
Exforge	Angiotensin 2 receptor blocker	119
Exforge HCT	Angiotensin 2 receptor blocker	97
Eylea	Vascular endothelial growth factor inhibitor	13
Foraseq		29
Formoterol fumarate	beta2-Adrenergic agonist	12
Forsteo		31
Forteo	Parathyroid hormone analog	37
Fortesta		122
Frontal		24
Galvus Met		28
Gilenya	Sphingosine 1-phosphate receptor modulator	15
Glivec		23
Heparin		13
Humalog	Insulin analog	16
Humira		344
Humulin N	Insulin	16
Hydrochlorothiazide	Thiazide diuretic	13
Hydrochlorothiazide Valsartan		14
Imbruvica	Kinase inhibitor	10
Indacaterol and Glycopyrrolate		18
Jakavi		12
Janumet	Biguanide	11
Januvia	Dipeptidyl peptidase 4 inhibitor	12
Kisqali	Kinase inhibitor	24
Lamictal	Anti-epileptic agent	212
Lamivudine	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	12
Lamotrigine	Anti-epileptic agent	75
Lantus	Insulin analog	48
Lantus Solostar	Insulin analog	15
Lipitor	HMG-CoA reductase inhibitor	230
Losartan	Angiotensin 2 receptor blocker	43
Lucentis	Vascular endothelial growth factor inhibitor	27
Lyrica		33
Mabthera		12
Metformin	Biguanide	25
Metformin Hydrochloride Vildagliptin		15
Methotrexate	Folate analog metabolic inhibitor	51
Methylprednisolone	Corticosteroid	12
Metoprolol	beta-Adrenergic blocker	23
Mycophenolate mofetil	Antimetabolite immunosuppressant	12
Nexium	Proton pump inhibitor	14
Olmetec		11
Onbrez		21
Pantoprazole	Proton pump inhibitor	13
Pradaxa	Direct thrombin inhibitor	51
Praluent	PCSK9 inhibitor	23
Prednisolone	Corticosteroid	28
Prednisone	Corticosteroid	37
Prolia	RANK ligand inhibitor	25
Quetiapine	Atypical antipsychotic	135
Quetiapine fumarate	Atypical antipsychotic	85
Rasilez		20
Rebif	Interferon beta	12
Remicade	Tumor necrosis factor blocker	42
Reopro		17
Repatha	PCSK9 inhibitor	11
Revlimid	Thalidomide analog	16
Revolade		10
Rilpivirine	Human immunodeficiency virus 1 Non-Nucleoside analog reverse transcriptase inhibitor	10
Rinvoq	Janus kinase inhibitor	26
Rituximab	CD20-directed cytolytic antibody	31
Rivotril		11
Rosuvastatin	HMG-CoA reductase inhibitor	10
Rotigotine	Nonergot dopamine agonist	21
Ruxolitinib	Janus kinase inhibitor	14
Sandostatin LAR Depot		18
Selozok		15
Seretide		29
Simvastatin	HMG-CoA reductase inhibitor	29
Skyrizi	Interleukin-23 antagonist	21
Stalevo		22
Stelara	Interleukin-12 antagonist	12
Striant		120
Sutent	Kinase inhibitor	15
Tacrolimus	Calcineurin inhibitor immunosuppressant	42
Tasigna	Kinase inhibitor	69
Testim	Androgen	126
Testopel	Androgen	120
Trileptal	Anti-epileptic agent	11
Varenicline tartrate	Partial cholinergic nicotinic agonist	14
Viagra	Phosphodiesterase 5 inhibitor	30
Vioxx		62
Vymada		25
Wellbutrin	Aminoketone	67
Xalatan	Prostaglandin analog	26
Xarelto	Factor Xa inhibitor	66
Xeljanz	Janus kinase inhibitor	18
Xolair	Anti-IgE	23
Zemplar	Vitamin D analog	253
Ziprasidone hydrochloride	Atypical antipsychotic	15
Zyprexa	Atypical antipsychotic	18

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 40 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Infarction name, in order of name
Class	Reports with this term
alpha-Adrenergic blocker	29
Aminoketone	230
Androgen	382
Angiotensin 2 receptor blocker	903
Anti-epileptic agent	310
Anti-IgE	29
Atypical antipsychotic	603
beta-Adrenergic blocker	54
Biguanide	49
Calcineurin inhibitor immunosuppressant	52
Calcium channel blocker	43
CD20-directed cytolytic antibody	43
Cholinesterase inhibitor	90
Corticosteroid	128
Direct thrombin inhibitor	51
Factor Xa inhibitor	204
Folate analog metabolic inhibitor	55
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	27
HMG-CoA reductase inhibitor	332
Insulin	29
Insulin analog	103
Interleukin-17A antagonist	78
Janus kinase inhibitor	64
Kinase inhibitor	171
Nonsteroidal anti-inflammatory drug	79
P2Y12 platelet inhibitor	211
Parathyroid hormone analog	40
PCSK9 inhibitor	36
Phosphodiesterase 5 inhibitor	42
Platelet aggregation inhibitor	57
Prostaglandin analog	26
Proton pump inhibitor	56
RANK ligand inhibitor	27
Selective T cell costimulation modulator	34
Serotonin reuptake inhibitor	26
Thalidomide analog	25
Thiazide diuretic	32
Tumor necrosis factor blocker	228
Vascular endothelial growth factor inhibitor	72
Vitamin D analog	253

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Infarction, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Infarction
Age	Reports	Share
Under 2	14	0.2%
2 to 11	23	0.3%
12 to 17	24	0.4%
18 to 44	456	6.7%
45 to 64	1,480	21.8%
65 to 74	1,062	15.6%
75 and over	1,044	15.4%
Age not given	2,697	39.7%

Sex of the patient in the reports that record Infarction
Sex	Reports	Share
Female	2,883	42.4%
Male	3,262	48%
Unknown or not given	655	9.6%

Age and sex are as the report gives them. 11.1% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Infarction: adverse event reports that record this term. https://reportedreactions.com/reaction/infarction/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Infarction mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page